Schering Temodar Confirmatory Trial To Test Combination Use With BCNU
A Phase IV confirmatory trial will explore the combination of Schering's Temodar (temozolomide) with BCNU in addition to comparing the oncologic agent to BCNU head to head in anaplastic astrocytoma. The trial is required following the accelerated approval of temozolomide Aug. 11.
You may also be interested in...
Correlation of symptom improvements to tumor response rate would be one way to demonstrate efficacy of Schering-Plough's Temodal in patients with malignant melanoma, members of FDA's Oncologic Drugs Advisory Committee suggested March 23.
Schering-Plough's Temodal (temozolomide) should be granted accelerated approval based on tumor response rates for treatment of anaplastic astrocytoma in patients who relapse following treatment with a nitrosourea (BCNU or CCNU) and procarbazine, the Oncologic Drugs Advisory Committee recommended Jan. 12.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011